The Tisch Cancer Institute at Mount Sinai | Strategic Alliance Partners

August 17, 2023

John Mascarenhas, MD, discusses the rationale for adding the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in patients receiving treatment for primary or secondary myelofibrosis who have previously had suboptimal responses with ruxolitinib.

August 04, 2023

Deborah B. Doroshow, MD, PhD, discusses the similarities and differences between the efficacy and safety profiles of pralsetinib and selpercatinib in patients with non–small cell lung cancer harboring RET fusions.

July 31, 2023

Marina Kremyanskaya, MD, PhD, details the outcomes of the phase 2 trial, expands on the potential implications for rusfertide in the treatment of patients with PV, and detailed the next steps for investigating the agent in this patient population.

July 29, 2023

Deborah B. Doroshow, MD, PhD, discusses the efficacy and toxicity profiles of pralsetinib and selpercatinib and how they influence treatment selection for patients with RET fusion–positive non–small cell lung cancer, and provides insight on several areas of ongoing or potential research in lung cancer.

July 20, 2023

Matthew Galsky, MD, discusses how updated findings from the phase 3 CheckMate 274 study confirm the efficacy of adjuvant systemic immunotherapy in metastatic urothelial carcinoma.

July 11, 2023

The Mount Sinai Health System's esophagectomy program has received a three-star overall composite score from the Society of Thoracic Surgeons.

July 10, 2023

Matthew Galsky, MD, discusses final results from the phase 3 IMvigor130 trial in patients with metastatic urothelial cancer.

July 07, 2023

John O. Mascarenhas, MD, discusses the design and rationale of the KRT-232-109 trial, key findings from the trial, and potential future directions of the study.

June 23, 2023

John Mascarenhas, MD, discusses initial clinical activity observed with the addition of the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in primary or secondary myelofibrosis.

June 16, 2023

Marina Kremyanskaya, MD, PhD, discusses key efficacy data for rusfertide in the phase 2 REVIVE trial of phlebotomy-dependent polycythemia vera.

June 11, 2023

Rusfertide demonstrated freedom from phlebotomy, sustained hematocrit control, and 12-week treatment completion in 69.2% vs 18.5% of patients with phlebotomy-dependent polycythemia vera who received placebo, meeting the primary end point of the phase 2 REVIVE trial.

May 24, 2023

Che-Kai Tsao, MD, discusses key updates from the phase 3 CheckMate 9ER trial, and how these data clarify the role of nivolumab plus cabozantinib as a new standard of care in renal cell carcinoma.

May 18, 2023

John Mascarenhas, MD, discusses ongoing trials and research in myelofibrosis.

May 16, 2023

Che-Kai Tsao, MD, discusses the investigation of cabozantinib in combination with nivolumab and ipilimumab in patients with renal cell carcinoma.

May 16, 2023

John Mascarenhas, MD, discusses first-line treatment decisions for patients with myelofibrosis.

May 15, 2023

Matthew Galsky, MD, discusses the importance of developing specific disease classifications within non–clear cell renal cell carcinomas.

May 11, 2023

John Mascarenhas, MD, discusses the background of the phase 3 MANIFEST-2 trial investigating the combination of pelabresib and ruxolitinib vs ruxolitinib plus placebo in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.

May 11, 2023

Che-Kai Tsao, MD, discusses first-line treatment approaches for patients with clear cell renal cell carcinoma.

May 08, 2023

Matthew Galsky, MD, explains how the development of novel drug classes and therapeutic combinations could address unmet needs in patients with metastatic renal cell carcinoma.

May 02, 2023

Matthew Galsky, MD, highlights updates in metastatic urothelial cancer treatment, as well as the evolution of PARP inhibitors and the optimal use of intensified triplet therapy in prostate cancer.